nodes	percent_of_prediction	percent_of_DWPC	metapath
Pazopanib—SLCO1B1—Methotrexate—psoriatic arthritis	0.0571	0.108	CbGbCtD
Pazopanib—ABCG2—Dexamethasone—psoriatic arthritis	0.0564	0.106	CbGbCtD
Pazopanib—ABCB1—Methylprednisolone—psoriatic arthritis	0.0538	0.101	CbGbCtD
Pazopanib—ABCG2—Methotrexate—psoriatic arthritis	0.0453	0.0855	CbGbCtD
Pazopanib—ABCB1—Betamethasone—psoriatic arthritis	0.035	0.0659	CbGbCtD
Pazopanib—ABCB1—Prednisolone—psoriatic arthritis	0.0345	0.065	CbGbCtD
Pazopanib—ABCB1—Prednisone—psoriatic arthritis	0.0326	0.0614	CbGbCtD
Pazopanib—CYP3A4—Methylprednisolone—psoriatic arthritis	0.0322	0.0607	CbGbCtD
Pazopanib—CYP2C8—Dexamethasone—psoriatic arthritis	0.0301	0.0566	CbGbCtD
Pazopanib—CYP3A4—Triamcinolone—psoriatic arthritis	0.0244	0.046	CbGbCtD
Pazopanib—CYP3A4—Betamethasone—psoriatic arthritis	0.021	0.0395	CbGbCtD
Pazopanib—CYP3A4—Prednisolone—psoriatic arthritis	0.0207	0.039	CbGbCtD
Pazopanib—ABCB1—Dexamethasone—psoriatic arthritis	0.0203	0.0383	CbGbCtD
Pazopanib—CYP3A4—Prednisone—psoriatic arthritis	0.0195	0.0368	CbGbCtD
Pazopanib—CYP2D6—Dexamethasone—psoriatic arthritis	0.0192	0.0361	CbGbCtD
Pazopanib—ABCB1—Methotrexate—psoriatic arthritis	0.0163	0.0308	CbGbCtD
Pazopanib—CYP3A4—Dexamethasone—psoriatic arthritis	0.0122	0.023	CbGbCtD
Pazopanib—FGFR3—skin of body—psoriatic arthritis	0.00164	0.0717	CbGeAlD
Pazopanib—SH2B3—tendon—psoriatic arthritis	0.00149	0.0652	CbGeAlD
Pazopanib—AURKC—tendon—psoriatic arthritis	0.00147	0.0642	CbGeAlD
Pazopanib—STK16—tendon—psoriatic arthritis	0.00127	0.0555	CbGeAlD
Pazopanib—RIOK2—tendon—psoriatic arthritis	0.00125	0.0546	CbGeAlD
Pazopanib—SH2B3—Dexamethasone—Methylprednisolone—psoriatic arthritis	0.00125	0.105	CbGdCrCtD
Pazopanib—SH2B3—Betamethasone—Methylprednisolone—psoriatic arthritis	0.00125	0.105	CbGdCrCtD
Pazopanib—SH2B3—Betamethasone—Dexamethasone—psoriatic arthritis	0.00123	0.104	CbGdCrCtD
Pazopanib—SH2B3—Dexamethasone—Betamethasone—psoriatic arthritis	0.00123	0.104	CbGdCrCtD
Pazopanib—SH2B3—Betamethasone—Triamcinolone—psoriatic arthritis	0.0012	0.101	CbGdCrCtD
Pazopanib—SH2B3—Dexamethasone—Triamcinolone—psoriatic arthritis	0.0012	0.101	CbGdCrCtD
Pazopanib—SH2B3—Dexamethasone—Prednisone—psoriatic arthritis	0.00114	0.0961	CbGdCrCtD
Pazopanib—SH2B3—Betamethasone—Prednisone—psoriatic arthritis	0.00114	0.0961	CbGdCrCtD
Pazopanib—FGF1—skin of body—psoriatic arthritis	0.00114	0.0497	CbGeAlD
Pazopanib—STK36—tendon—psoriatic arthritis	0.00112	0.049	CbGeAlD
Pazopanib—SH2B3—Betamethasone—Prednisolone—psoriatic arthritis	0.00111	0.0938	CbGdCrCtD
Pazopanib—SH2B3—Dexamethasone—Prednisolone—psoriatic arthritis	0.00111	0.0938	CbGdCrCtD
Pazopanib—PI4KB—tendon—psoriatic arthritis	0.00111	0.0483	CbGeAlD
Pazopanib—FGFR2—skin of body—psoriatic arthritis	0.00107	0.0469	CbGeAlD
Pazopanib—EPHB6—skin of body—psoriatic arthritis	0.000985	0.043	CbGeAlD
Pazopanib—PIP4K2C—tendon—psoriatic arthritis	0.00097	0.0424	CbGeAlD
Pazopanib—FGFR1—tendon—psoriatic arthritis	0.000962	0.042	CbGeAlD
Pazopanib—CSF1R—skin of body—psoriatic arthritis	0.000822	0.0359	CbGeAlD
Pazopanib—FLT1—tendon—psoriatic arthritis	0.000758	0.0331	CbGeAlD
Pazopanib—EPHB6—tendon—psoriatic arthritis	0.00075	0.0327	CbGeAlD
Pazopanib—KIT—skin of body—psoriatic arthritis	0.000746	0.0326	CbGeAlD
Pazopanib—PDGFRB—skin of body—psoriatic arthritis	0.000729	0.0318	CbGeAlD
Pazopanib—STK10—tendon—psoriatic arthritis	0.000718	0.0314	CbGeAlD
Pazopanib—TAOK3—tendon—psoriatic arthritis	0.000715	0.0312	CbGeAlD
Pazopanib—PDGFRA—tendon—psoriatic arthritis	0.000711	0.031	CbGeAlD
Pazopanib—KDR—tendon—psoriatic arthritis	0.000641	0.028	CbGeAlD
Pazopanib—MAP2K5—tendon—psoriatic arthritis	0.000641	0.028	CbGeAlD
Pazopanib—CSF1R—tendon—psoriatic arthritis	0.000626	0.0273	CbGeAlD
Pazopanib—FGFR2—Downstream signaling events of B Cell Receptor (BCR)—REL—psoriatic arthritis	0.000578	0.00599	CbGpPWpGaD
Pazopanib—Haemorrhage—Betamethasone—psoriatic arthritis	0.000571	0.00169	CcSEcCtD
Pazopanib—Haemorrhage—Dexamethasone—psoriatic arthritis	0.000571	0.00169	CcSEcCtD
Pazopanib—Angiopathy—Methylprednisolone—psoriatic arthritis	0.00057	0.00168	CcSEcCtD
Pazopanib—KIT—Downstream signaling events of B Cell Receptor (BCR)—REL—psoriatic arthritis	0.000568	0.00589	CbGpPWpGaD
Pazopanib—Mediastinal disorder—Methylprednisolone—psoriatic arthritis	0.000566	0.00167	CcSEcCtD
Pazopanib—Weight decreased—Prednisone—psoriatic arthritis	0.000562	0.00166	CcSEcCtD
Pazopanib—Vision blurred—Prednisolone—psoriatic arthritis	0.000562	0.00166	CcSEcCtD
Pazopanib—FGFR3—Innate Immune System—MEFV—psoriatic arthritis	0.00056	0.00581	CbGpPWpGaD
Pazopanib—Liver function test abnormal—Methotrexate—psoriatic arthritis	0.000555	0.00164	CcSEcCtD
Pazopanib—PDGFRB—tendon—psoriatic arthritis	0.000555	0.0242	CbGeAlD
Pazopanib—Mental disorder—Methylprednisolone—psoriatic arthritis	0.00055	0.00163	CcSEcCtD
Pazopanib—LCK—Downstream TCR signaling—HLA-DRB1—psoriatic arthritis	0.00055	0.00571	CbGpPWpGaD
Pazopanib—Erythema—Triamcinolone—psoriatic arthritis	0.000548	0.00162	CcSEcCtD
Pazopanib—Erythema—Methylprednisolone—psoriatic arthritis	0.000547	0.00162	CcSEcCtD
Pazopanib—Malnutrition—Methylprednisolone—psoriatic arthritis	0.000547	0.00162	CcSEcCtD
Pazopanib—Acute coronary syndrome—Prednisone—psoriatic arthritis	0.000546	0.00161	CcSEcCtD
Pazopanib—Myocardial infarction—Prednisone—psoriatic arthritis	0.000543	0.00161	CcSEcCtD
Pazopanib—Breast disorder—Methotrexate—psoriatic arthritis	0.000543	0.00161	CcSEcCtD
Pazopanib—PDGFRA—ATF-2 transcription factor network—NOS2—psoriatic arthritis	0.000542	0.00562	CbGpPWpGaD
Pazopanib—FGFR1—Downstream signaling events of B Cell Receptor (BCR)—REL—psoriatic arthritis	0.000539	0.00559	CbGpPWpGaD
Pazopanib—PDGFRA—Downstream signaling events of B Cell Receptor (BCR)—REL—psoriatic arthritis	0.000537	0.00557	CbGpPWpGaD
Pazopanib—Dysgeusia—Triamcinolone—psoriatic arthritis	0.000537	0.00159	CcSEcCtD
Pazopanib—Syncope—Prednisolone—psoriatic arthritis	0.000535	0.00158	CcSEcCtD
Pazopanib—Eye disorder—Betamethasone—psoriatic arthritis	0.000534	0.00158	CcSEcCtD
Pazopanib—Eye disorder—Dexamethasone—psoriatic arthritis	0.000534	0.00158	CcSEcCtD
Pazopanib—ITK—Adaptive Immune System—REL—psoriatic arthritis	0.000534	0.00554	CbGpPWpGaD
Pazopanib—PDGFRA—Allograft Rejection—HLA-B—psoriatic arthritis	0.000532	0.00552	CbGpPWpGaD
Pazopanib—Loss of consciousness—Prednisolone—psoriatic arthritis	0.000524	0.00155	CcSEcCtD
Pazopanib—Angiopathy—Dexamethasone—psoriatic arthritis	0.000518	0.00153	CcSEcCtD
Pazopanib—Angiopathy—Betamethasone—psoriatic arthritis	0.000518	0.00153	CcSEcCtD
Pazopanib—Hypertension—Prednisolone—psoriatic arthritis	0.000515	0.00152	CcSEcCtD
Pazopanib—ITK—Innate Immune System—HLA-C—psoriatic arthritis	0.000512	0.00531	CbGpPWpGaD
Pazopanib—FGFR2—B Cell Activation—REL—psoriatic arthritis	0.000511	0.0053	CbGpPWpGaD
Pazopanib—Pancreatitis—Methotrexate—psoriatic arthritis	0.000509	0.00151	CcSEcCtD
Pazopanib—FGFR2—DAP12 interactions—HLA-C—psoriatic arthritis	0.000508	0.00527	CbGpPWpGaD
Pazopanib—Bradycardia—Prednisone—psoriatic arthritis	0.000507	0.0015	CcSEcCtD
Pazopanib—Alopecia—Dexamethasone—psoriatic arthritis	0.000505	0.00149	CcSEcCtD
Pazopanib—Alopecia—Betamethasone—psoriatic arthritis	0.000505	0.00149	CcSEcCtD
Pazopanib—KIT—B Cell Activation—REL—psoriatic arthritis	0.000501	0.0052	CbGpPWpGaD
Pazopanib—Haemoglobin—Prednisone—psoriatic arthritis	0.0005	0.00148	CcSEcCtD
Pazopanib—KIT—DAP12 interactions—HLA-C—psoriatic arthritis	0.000499	0.00517	CbGpPWpGaD
Pazopanib—Haemorrhage—Prednisone—psoriatic arthritis	0.000498	0.00147	CcSEcCtD
Pazopanib—Erythema—Betamethasone—psoriatic arthritis	0.000497	0.00147	CcSEcCtD
Pazopanib—Erythema—Dexamethasone—psoriatic arthritis	0.000497	0.00147	CcSEcCtD
Pazopanib—Syncope—Triamcinolone—psoriatic arthritis	0.000492	0.00145	CcSEcCtD
Pazopanib—ITK—Adaptive Immune System—HLA-C—psoriatic arthritis	0.000491	0.0051	CbGpPWpGaD
Pazopanib—Syncope—Methylprednisolone—psoriatic arthritis	0.00049	0.00145	CcSEcCtD
Pazopanib—Connective tissue disorder—Prednisone—psoriatic arthritis	0.000489	0.00145	CcSEcCtD
Pazopanib—Oedema—Prednisolone—psoriatic arthritis	0.000486	0.00144	CcSEcCtD
Pazopanib—Neutropenia—Methotrexate—psoriatic arthritis	0.000486	0.00144	CcSEcCtD
Pazopanib—PDGFRB—Downstream signaling events of B Cell Receptor (BCR)—REL—psoriatic arthritis	0.000484	0.00502	CbGpPWpGaD
Pazopanib—Loss of consciousness—Triamcinolone—psoriatic arthritis	0.000482	0.00142	CcSEcCtD
Pazopanib—Loss of consciousness—Methylprednisolone—psoriatic arthritis	0.000481	0.00142	CcSEcCtD
Pazopanib—Shock—Prednisolone—psoriatic arthritis	0.000479	0.00141	CcSEcCtD
Pazopanib—Cough—Triamcinolone—psoriatic arthritis	0.000478	0.00141	CcSEcCtD
Pazopanib—FGFR1—B Cell Activation—REL—psoriatic arthritis	0.000476	0.00494	CbGpPWpGaD
Pazopanib—PDGFRA—B Cell Activation—REL—psoriatic arthritis	0.000475	0.00492	CbGpPWpGaD
Pazopanib—Photosensitivity reaction—Methotrexate—psoriatic arthritis	0.000474	0.0014	CcSEcCtD
Pazopanib—Hypertension—Triamcinolone—psoriatic arthritis	0.000473	0.0014	CcSEcCtD
Pazopanib—FGFR1—DAP12 interactions—HLA-C—psoriatic arthritis	0.000473	0.00491	CbGpPWpGaD
Pazopanib—Hypertension—Methylprednisolone—psoriatic arthritis	0.000472	0.0014	CcSEcCtD
Pazopanib—PDGFRA—DAP12 interactions—HLA-C—psoriatic arthritis	0.000472	0.0049	CbGpPWpGaD
Pazopanib—Hyperhidrosis—Prednisolone—psoriatic arthritis	0.00047	0.00139	CcSEcCtD
Pazopanib—Myalgia—Triamcinolone—psoriatic arthritis	0.000467	0.00138	CcSEcCtD
Pazopanib—Arthralgia—Methylprednisolone—psoriatic arthritis	0.000466	0.00138	CcSEcCtD
Pazopanib—Myalgia—Methylprednisolone—psoriatic arthritis	0.000466	0.00138	CcSEcCtD
Pazopanib—FGF1—Innate Immune System—MEFV—psoriatic arthritis	0.000466	0.00483	CbGpPWpGaD
Pazopanib—Eye disorder—Prednisone—psoriatic arthritis	0.000465	0.00137	CcSEcCtD
Pazopanib—Infestation NOS—Methotrexate—psoriatic arthritis	0.000463	0.00137	CcSEcCtD
Pazopanib—Infestation—Methotrexate—psoriatic arthritis	0.000463	0.00137	CcSEcCtD
Pazopanib—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—psoriatic arthritis	0.000462	0.00137	CcSEcCtD
Pazopanib—Flushing—Prednisone—psoriatic arthritis	0.000462	0.00136	CcSEcCtD
Pazopanib—Dry mouth—Triamcinolone—psoriatic arthritis	0.000456	0.00135	CcSEcCtD
Pazopanib—LYN—Signaling by Interleukins—NOD2—psoriatic arthritis	0.000455	0.00471	CbGpPWpGaD
Pazopanib—Stomatitis—Methotrexate—psoriatic arthritis	0.000452	0.00133	CcSEcCtD
Pazopanib—Angiopathy—Prednisone—psoriatic arthritis	0.000451	0.00133	CcSEcCtD
Pazopanib—PDGFRA—Allograft Rejection—HLA-DRB1—psoriatic arthritis	0.00045	0.00467	CbGpPWpGaD
Pazopanib—LYN—Costimulation by the CD28 family—HLA-DRB1—psoriatic arthritis	0.000448	0.00465	CbGpPWpGaD
Pazopanib—Oedema—Triamcinolone—psoriatic arthritis	0.000447	0.00132	CcSEcCtD
Pazopanib—Syncope—Dexamethasone—psoriatic arthritis	0.000446	0.00132	CcSEcCtD
Pazopanib—Syncope—Betamethasone—psoriatic arthritis	0.000446	0.00132	CcSEcCtD
Pazopanib—Infection—Triamcinolone—psoriatic arthritis	0.000444	0.00131	CcSEcCtD
Pazopanib—TAOK1—MAPK Signaling Pathway—TNF—psoriatic arthritis	0.000444	0.0046	CbGpPWpGaD
Pazopanib—Infection—Methylprednisolone—psoriatic arthritis	0.000443	0.00131	CcSEcCtD
Pazopanib—Haematuria—Methotrexate—psoriatic arthritis	0.000442	0.00131	CcSEcCtD
Pazopanib—Shock—Triamcinolone—psoriatic arthritis	0.00044	0.0013	CcSEcCtD
Pazopanib—Insomnia—Prednisolone—psoriatic arthritis	0.00044	0.0013	CcSEcCtD
Pazopanib—Alopecia—Prednisone—psoriatic arthritis	0.00044	0.0013	CcSEcCtD
Pazopanib—Shock—Methylprednisolone—psoriatic arthritis	0.000439	0.0013	CcSEcCtD
Pazopanib—Hepatobiliary disease—Methotrexate—psoriatic arthritis	0.000438	0.00129	CcSEcCtD
Pazopanib—Nervous system disorder—Methylprednisolone—psoriatic arthritis	0.000438	0.00129	CcSEcCtD
Pazopanib—Loss of consciousness—Betamethasone—psoriatic arthritis	0.000437	0.00129	CcSEcCtD
Pazopanib—Loss of consciousness—Dexamethasone—psoriatic arthritis	0.000437	0.00129	CcSEcCtD
Pazopanib—Epistaxis—Methotrexate—psoriatic arthritis	0.000437	0.00129	CcSEcCtD
Pazopanib—Paraesthesia—Prednisolone—psoriatic arthritis	0.000437	0.00129	CcSEcCtD
Pazopanib—FGFR3—DAP12 interactions—HLA-B—psoriatic arthritis	0.000437	0.00453	CbGpPWpGaD
Pazopanib—Mental disorder—Prednisone—psoriatic arthritis	0.000436	0.00129	CcSEcCtD
Pazopanib—Skin disorder—Methylprednisolone—psoriatic arthritis	0.000434	0.00128	CcSEcCtD
Pazopanib—Erythema—Prednisone—psoriatic arthritis	0.000433	0.00128	CcSEcCtD
Pazopanib—Malnutrition—Prednisone—psoriatic arthritis	0.000433	0.00128	CcSEcCtD
Pazopanib—Hyperhidrosis—Triamcinolone—psoriatic arthritis	0.000432	0.00128	CcSEcCtD
Pazopanib—Hyperhidrosis—Methylprednisolone—psoriatic arthritis	0.000432	0.00128	CcSEcCtD
Pazopanib—Hypertension—Dexamethasone—psoriatic arthritis	0.000429	0.00127	CcSEcCtD
Pazopanib—Hypertension—Betamethasone—psoriatic arthritis	0.000429	0.00127	CcSEcCtD
Pazopanib—PDGFRB—B Cell Activation—REL—psoriatic arthritis	0.000428	0.00443	CbGpPWpGaD
Pazopanib—PDGFRB—DAP12 interactions—HLA-C—psoriatic arthritis	0.000425	0.00441	CbGpPWpGaD
Pazopanib—Myalgia—Betamethasone—psoriatic arthritis	0.000423	0.00125	CcSEcCtD
Pazopanib—Myalgia—Dexamethasone—psoriatic arthritis	0.000423	0.00125	CcSEcCtD
Pazopanib—SH2B3—Hemostasis—NOS2—psoriatic arthritis	0.00042	0.00436	CbGpPWpGaD
Pazopanib—LYN—B Cell Activation—REL—psoriatic arthritis	0.000419	0.00434	CbGpPWpGaD
Pazopanib—Haemoglobin—Methotrexate—psoriatic arthritis	0.000418	0.00124	CcSEcCtD
Pazopanib—Pain—Prednisolone—psoriatic arthritis	0.000416	0.00123	CcSEcCtD
Pazopanib—Haemorrhage—Methotrexate—psoriatic arthritis	0.000416	0.00123	CcSEcCtD
Pazopanib—LCK—TCR signaling—HLA-DRB1—psoriatic arthritis	0.000411	0.00427	CbGpPWpGaD
Pazopanib—Urinary tract disorder—Methotrexate—psoriatic arthritis	0.000411	0.00121	CcSEcCtD
Pazopanib—Vision blurred—Prednisone—psoriatic arthritis	0.000408	0.00121	CcSEcCtD
Pazopanib—Urethral disorder—Methotrexate—psoriatic arthritis	0.000408	0.0012	CcSEcCtD
Pazopanib—Musculoskeletal discomfort—Triamcinolone—psoriatic arthritis	0.000408	0.0012	CcSEcCtD
Pazopanib—Musculoskeletal discomfort—Methylprednisolone—psoriatic arthritis	0.000407	0.0012	CcSEcCtD
Pazopanib—Oedema—Betamethasone—psoriatic arthritis	0.000406	0.0012	CcSEcCtD
Pazopanib—Oedema—Dexamethasone—psoriatic arthritis	0.000406	0.0012	CcSEcCtD
Pazopanib—LCK—IL12-mediated signaling events—HLA-DRB1—psoriatic arthritis	0.000406	0.00421	CbGpPWpGaD
Pazopanib—Insomnia—Triamcinolone—psoriatic arthritis	0.000405	0.0012	CcSEcCtD
Pazopanib—Insomnia—Methylprednisolone—psoriatic arthritis	0.000404	0.00119	CcSEcCtD
Pazopanib—Infection—Betamethasone—psoriatic arthritis	0.000403	0.00119	CcSEcCtD
Pazopanib—Infection—Dexamethasone—psoriatic arthritis	0.000403	0.00119	CcSEcCtD
Pazopanib—Paraesthesia—Triamcinolone—psoriatic arthritis	0.000402	0.00119	CcSEcCtD
Pazopanib—Paraesthesia—Methylprednisolone—psoriatic arthritis	0.000401	0.00118	CcSEcCtD
Pazopanib—Anaemia—Prednisone—psoriatic arthritis	0.0004	0.00118	CcSEcCtD
Pazopanib—Shock—Dexamethasone—psoriatic arthritis	0.000399	0.00118	CcSEcCtD
Pazopanib—Shock—Betamethasone—psoriatic arthritis	0.000399	0.00118	CcSEcCtD
Pazopanib—Dyspnoea—Triamcinolone—psoriatic arthritis	0.000399	0.00118	CcSEcCtD
Pazopanib—Nervous system disorder—Dexamethasone—psoriatic arthritis	0.000398	0.00118	CcSEcCtD
Pazopanib—Nervous system disorder—Betamethasone—psoriatic arthritis	0.000398	0.00118	CcSEcCtD
Pazopanib—MAP2K5—Cardiac Hypertrophic Response—TNF—psoriatic arthritis	0.000398	0.00413	CbGpPWpGaD
Pazopanib—Thrombocytopenia—Dexamethasone—psoriatic arthritis	0.000397	0.00117	CcSEcCtD
Pazopanib—Thrombocytopenia—Betamethasone—psoriatic arthritis	0.000397	0.00117	CcSEcCtD
Pazopanib—Dyspepsia—Triamcinolone—psoriatic arthritis	0.000394	0.00116	CcSEcCtD
Pazopanib—Dyspepsia—Methylprednisolone—psoriatic arthritis	0.000393	0.00116	CcSEcCtD
Pazopanib—Hyperhidrosis—Dexamethasone—psoriatic arthritis	0.000392	0.00116	CcSEcCtD
Pazopanib—Hyperhidrosis—Betamethasone—psoriatic arthritis	0.000392	0.00116	CcSEcCtD
Pazopanib—Eye disorder—Methotrexate—psoriatic arthritis	0.000389	0.00115	CcSEcCtD
Pazopanib—LCK—Downstream signaling events of B Cell Receptor (BCR)—REL—psoriatic arthritis	0.000388	0.00403	CbGpPWpGaD
Pazopanib—Syncope—Prednisone—psoriatic arthritis	0.000388	0.00115	CcSEcCtD
Pazopanib—Anorexia—Betamethasone—psoriatic arthritis	0.000387	0.00114	CcSEcCtD
Pazopanib—Anorexia—Dexamethasone—psoriatic arthritis	0.000387	0.00114	CcSEcCtD
Pazopanib—LCK—IL12-mediated signaling events—NOS2—psoriatic arthritis	0.000386	0.00401	CbGpPWpGaD
Pazopanib—Cardiac disorder—Methotrexate—psoriatic arthritis	0.000386	0.00114	CcSEcCtD
Pazopanib—Fatigue—Triamcinolone—psoriatic arthritis	0.000386	0.00114	CcSEcCtD
Pazopanib—FGFR2—Innate Immune System—MEFV—psoriatic arthritis	0.000385	0.004	CbGpPWpGaD
Pazopanib—Fatigue—Methylprednisolone—psoriatic arthritis	0.000385	0.00114	CcSEcCtD
Pazopanib—Pain—Triamcinolone—psoriatic arthritis	0.000383	0.00113	CcSEcCtD
Pazopanib—Loss of consciousness—Prednisone—psoriatic arthritis	0.000381	0.00113	CcSEcCtD
Pazopanib—KIT—Innate Immune System—MEFV—psoriatic arthritis	0.000378	0.00393	CbGpPWpGaD
Pazopanib—LYN—CXCR4-mediated signaling events—HLA-DRB1—psoriatic arthritis	0.000378	0.00392	CbGpPWpGaD
Pazopanib—Angiopathy—Methotrexate—psoriatic arthritis	0.000377	0.00112	CcSEcCtD
Pazopanib—ITK—Innate Immune System—NOD2—psoriatic arthritis	0.000376	0.0039	CbGpPWpGaD
Pazopanib—LCK—TCR signaling in naïve CD4+ T cells—HLA-DRB1—psoriatic arthritis	0.000376	0.0039	CbGpPWpGaD
Pazopanib—Mediastinal disorder—Methotrexate—psoriatic arthritis	0.000375	0.00111	CcSEcCtD
Pazopanib—Hypertension—Prednisone—psoriatic arthritis	0.000374	0.00111	CcSEcCtD
Pazopanib—Chills—Methotrexate—psoriatic arthritis	0.000373	0.0011	CcSEcCtD
Pazopanib—LCK—Signaling by Interleukins—NOD2—psoriatic arthritis	0.000373	0.00386	CbGpPWpGaD
Pazopanib—Musculoskeletal discomfort—Betamethasone—psoriatic arthritis	0.00037	0.00109	CcSEcCtD
Pazopanib—Musculoskeletal discomfort—Dexamethasone—psoriatic arthritis	0.00037	0.00109	CcSEcCtD
Pazopanib—Arthralgia—Prednisone—psoriatic arthritis	0.000369	0.00109	CcSEcCtD
Pazopanib—Myalgia—Prednisone—psoriatic arthritis	0.000369	0.00109	CcSEcCtD
Pazopanib—Alopecia—Methotrexate—psoriatic arthritis	0.000367	0.00109	CcSEcCtD
Pazopanib—LCK—Costimulation by the CD28 family—HLA-DRB1—psoriatic arthritis	0.000367	0.00381	CbGpPWpGaD
Pazopanib—Insomnia—Betamethasone—psoriatic arthritis	0.000367	0.00109	CcSEcCtD
Pazopanib—Insomnia—Dexamethasone—psoriatic arthritis	0.000367	0.00109	CcSEcCtD
Pazopanib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriatic arthritis	0.000366	0.00108	CcSEcCtD
Pazopanib—Gastrointestinal pain—Methylprednisolone—psoriatic arthritis	0.000365	0.00108	CcSEcCtD
Pazopanib—Paraesthesia—Dexamethasone—psoriatic arthritis	0.000364	0.00108	CcSEcCtD
Pazopanib—Paraesthesia—Betamethasone—psoriatic arthritis	0.000364	0.00108	CcSEcCtD
Pazopanib—Mental disorder—Methotrexate—psoriatic arthritis	0.000364	0.00108	CcSEcCtD
Pazopanib—FGF1—DAP12 interactions—HLA-B—psoriatic arthritis	0.000363	0.00376	CbGpPWpGaD
Pazopanib—Malnutrition—Methotrexate—psoriatic arthritis	0.000362	0.00107	CcSEcCtD
Pazopanib—Erythema—Methotrexate—psoriatic arthritis	0.000362	0.00107	CcSEcCtD
Pazopanib—FGFR1—Innate Immune System—MEFV—psoriatic arthritis	0.000359	0.00373	CbGpPWpGaD
Pazopanib—PDGFRA—Innate Immune System—MEFV—psoriatic arthritis	0.000358	0.00372	CbGpPWpGaD
Pazopanib—Dyspepsia—Dexamethasone—psoriatic arthritis	0.000357	0.00106	CcSEcCtD
Pazopanib—Dyspepsia—Betamethasone—psoriatic arthritis	0.000357	0.00106	CcSEcCtD
Pazopanib—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL12B—psoriatic arthritis	0.000357	0.0037	CbGpPWpGaD
Pazopanib—Dysgeusia—Methotrexate—psoriatic arthritis	0.000354	0.00105	CcSEcCtD
Pazopanib—Oedema—Prednisone—psoriatic arthritis	0.000353	0.00104	CcSEcCtD
Pazopanib—Abdominal pain—Methylprednisolone—psoriatic arthritis	0.000353	0.00104	CcSEcCtD
Pazopanib—Decreased appetite—Betamethasone—psoriatic arthritis	0.000353	0.00104	CcSEcCtD
Pazopanib—Decreased appetite—Dexamethasone—psoriatic arthritis	0.000353	0.00104	CcSEcCtD
Pazopanib—Infection—Prednisone—psoriatic arthritis	0.000351	0.00104	CcSEcCtD
Pazopanib—Gastrointestinal disorder—Betamethasone—psoriatic arthritis	0.00035	0.00104	CcSEcCtD
Pazopanib—Gastrointestinal disorder—Dexamethasone—psoriatic arthritis	0.00035	0.00104	CcSEcCtD
Pazopanib—Fatigue—Betamethasone—psoriatic arthritis	0.00035	0.00103	CcSEcCtD
Pazopanib—Fatigue—Dexamethasone—psoriatic arthritis	0.00035	0.00103	CcSEcCtD
Pazopanib—Shock—Prednisone—psoriatic arthritis	0.000348	0.00103	CcSEcCtD
Pazopanib—Pain—Betamethasone—psoriatic arthritis	0.000347	0.00103	CcSEcCtD
Pazopanib—Pain—Dexamethasone—psoriatic arthritis	0.000347	0.00103	CcSEcCtD
Pazopanib—ABCG2—HIF-1-alpha transcription factor network—NOS2—psoriatic arthritis	0.000347	0.0036	CbGpPWpGaD
Pazopanib—Nervous system disorder—Prednisone—psoriatic arthritis	0.000347	0.00102	CcSEcCtD
Pazopanib—Skin disorder—Prednisone—psoriatic arthritis	0.000343	0.00101	CcSEcCtD
Pazopanib—LCK—B Cell Activation—REL—psoriatic arthritis	0.000343	0.00356	CbGpPWpGaD
Pazopanib—Hyperhidrosis—Prednisone—psoriatic arthritis	0.000342	0.00101	CcSEcCtD
Pazopanib—LCK—DAP12 interactions—HLA-C—psoriatic arthritis	0.000341	0.00354	CbGpPWpGaD
Pazopanib—Vision blurred—Methotrexate—psoriatic arthritis	0.000341	0.00101	CcSEcCtD
Pazopanib—ABCB1—Allograft Rejection—HLA-C—psoriatic arthritis	0.000341	0.00353	CbGpPWpGaD
Pazopanib—ABCB1—Allograft Rejection—IL13—psoriatic arthritis	0.000339	0.00351	CbGpPWpGaD
Pazopanib—Anorexia—Prednisone—psoriatic arthritis	0.000337	0.000996	CcSEcCtD
Pazopanib—Anaemia—Methotrexate—psoriatic arthritis	0.000335	0.000989	CcSEcCtD
Pazopanib—Gastrointestinal pain—Dexamethasone—psoriatic arthritis	0.000332	0.000981	CcSEcCtD
Pazopanib—Gastrointestinal pain—Betamethasone—psoriatic arthritis	0.000332	0.000981	CcSEcCtD
Pazopanib—FGFR3—Immune System—MEFV—psoriatic arthritis	0.000326	0.00338	CbGpPWpGaD
Pazopanib—Leukopenia—Methotrexate—psoriatic arthritis	0.000324	0.000958	CcSEcCtD
Pazopanib—ITK—Immune System—REL—psoriatic arthritis	0.000324	0.00336	CbGpPWpGaD
Pazopanib—PDGFRB—Innate Immune System—MEFV—psoriatic arthritis	0.000323	0.00335	CbGpPWpGaD
Pazopanib—Musculoskeletal discomfort—Prednisone—psoriatic arthritis	0.000322	0.000952	CcSEcCtD
Pazopanib—Dizziness—Prednisolone—psoriatic arthritis	0.000322	0.000951	CcSEcCtD
Pazopanib—Asthenia—Triamcinolone—psoriatic arthritis	0.000321	0.000949	CcSEcCtD
Pazopanib—Abdominal pain—Betamethasone—psoriatic arthritis	0.000321	0.000948	CcSEcCtD
Pazopanib—Abdominal pain—Dexamethasone—psoriatic arthritis	0.000321	0.000948	CcSEcCtD
Pazopanib—Asthenia—Methylprednisolone—psoriatic arthritis	0.00032	0.000947	CcSEcCtD
Pazopanib—Insomnia—Prednisone—psoriatic arthritis	0.00032	0.000945	CcSEcCtD
Pazopanib—Paraesthesia—Prednisone—psoriatic arthritis	0.000317	0.000938	CcSEcCtD
Pazopanib—Pruritus—Triamcinolone—psoriatic arthritis	0.000317	0.000935	CcSEcCtD
Pazopanib—LYN—Innate Immune System—MEFV—psoriatic arthritis	0.000316	0.00328	CbGpPWpGaD
Pazopanib—Cough—Methotrexate—psoriatic arthritis	0.000316	0.000934	CcSEcCtD
Pazopanib—Pruritus—Methylprednisolone—psoriatic arthritis	0.000316	0.000933	CcSEcCtD
Pazopanib—ABCB1—Allograft Rejection—IL17A—psoriatic arthritis	0.000312	0.00323	CbGpPWpGaD
Pazopanib—Dyspepsia—Prednisone—psoriatic arthritis	0.000311	0.00092	CcSEcCtD
Pazopanib—LCK—CXCR4-mediated signaling events—HLA-DRB1—psoriatic arthritis	0.00031	0.00322	CbGpPWpGaD
Pazopanib—Myalgia—Methotrexate—psoriatic arthritis	0.000308	0.000911	CcSEcCtD
Pazopanib—Arthralgia—Methotrexate—psoriatic arthritis	0.000308	0.000911	CcSEcCtD
Pazopanib—Chest pain—Methotrexate—psoriatic arthritis	0.000308	0.000911	CcSEcCtD
Pazopanib—Decreased appetite—Prednisone—psoriatic arthritis	0.000307	0.000908	CcSEcCtD
Pazopanib—Rash—Prednisolone—psoriatic arthritis	0.000307	0.000907	CcSEcCtD
Pazopanib—Dermatitis—Prednisolone—psoriatic arthritis	0.000306	0.000906	CcSEcCtD
Pazopanib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriatic arthritis	0.000306	0.000905	CcSEcCtD
Pazopanib—FGFR2—Cardiac Hypertrophic Response—TNF—psoriatic arthritis	0.000306	0.00317	CbGpPWpGaD
Pazopanib—Diarrhoea—Methylprednisolone—psoriatic arthritis	0.000305	0.000903	CcSEcCtD
Pazopanib—Fatigue—Prednisone—psoriatic arthritis	0.000305	0.000901	CcSEcCtD
Pazopanib—Headache—Prednisolone—psoriatic arthritis	0.000305	0.000901	CcSEcCtD
Pazopanib—ITK—Innate Immune System—HLA-B—psoriatic arthritis	0.000303	0.00314	CbGpPWpGaD
Pazopanib—FGFR2—DAP12 interactions—HLA-B—psoriatic arthritis	0.0003	0.00311	CbGpPWpGaD
Pazopanib—FGFR3—Adaptive Immune System—REL—psoriatic arthritis	0.000299	0.0031	CbGpPWpGaD
Pazopanib—ITK—Immune System—HLA-C—psoriatic arthritis	0.000298	0.00309	CbGpPWpGaD
Pazopanib—Dizziness—Triamcinolone—psoriatic arthritis	0.000296	0.000874	CcSEcCtD
Pazopanib—Dizziness—Methylprednisolone—psoriatic arthritis	0.000295	0.000872	CcSEcCtD
Pazopanib—KIT—DAP12 interactions—HLA-B—psoriatic arthritis	0.000295	0.00306	CbGpPWpGaD
Pazopanib—Infection—Methotrexate—psoriatic arthritis	0.000294	0.000867	CcSEcCtD
Pazopanib—Asthenia—Betamethasone—psoriatic arthritis	0.000291	0.000861	CcSEcCtD
Pazopanib—Asthenia—Dexamethasone—psoriatic arthritis	0.000291	0.000861	CcSEcCtD
Pazopanib—ITK—Adaptive Immune System—HLA-B—psoriatic arthritis	0.000291	0.00301	CbGpPWpGaD
Pazopanib—ABCB1—Allograft Rejection—IL12B—psoriatic arthritis	0.00029	0.00301	CbGpPWpGaD
Pazopanib—Nervous system disorder—Methotrexate—psoriatic arthritis	0.00029	0.000856	CcSEcCtD
Pazopanib—Thrombocytopenia—Methotrexate—psoriatic arthritis	0.000289	0.000855	CcSEcCtD
Pazopanib—Gastrointestinal pain—Prednisone—psoriatic arthritis	0.000289	0.000854	CcSEcCtD
Pazopanib—Nausea—Prednisolone—psoriatic arthritis	0.000289	0.000854	CcSEcCtD
Pazopanib—LYN—Cytokine Signaling in Immune system—HLA-C—psoriatic arthritis	0.000288	0.00299	CbGpPWpGaD
Pazopanib—Pruritus—Dexamethasone—psoriatic arthritis	0.000287	0.000849	CcSEcCtD
Pazopanib—Pruritus—Betamethasone—psoriatic arthritis	0.000287	0.000849	CcSEcCtD
Pazopanib—Skin disorder—Methotrexate—psoriatic arthritis	0.000287	0.000848	CcSEcCtD
Pazopanib—FGFR3—Innate Immune System—HLA-C—psoriatic arthritis	0.000287	0.00297	CbGpPWpGaD
Pazopanib—Hyperhidrosis—Methotrexate—psoriatic arthritis	0.000286	0.000844	CcSEcCtD
Pazopanib—Vomiting—Triamcinolone—psoriatic arthritis	0.000284	0.000841	CcSEcCtD
Pazopanib—Vomiting—Methylprednisolone—psoriatic arthritis	0.000284	0.000839	CcSEcCtD
Pazopanib—MAP2K5—MicroRNAs in cardiomyocyte hypertrophy—TNF—psoriatic arthritis	0.000283	0.00294	CbGpPWpGaD
Pazopanib—Rash—Triamcinolone—psoriatic arthritis	0.000282	0.000834	CcSEcCtD
Pazopanib—Dermatitis—Triamcinolone—psoriatic arthritis	0.000282	0.000833	CcSEcCtD
Pazopanib—Anorexia—Methotrexate—psoriatic arthritis	0.000282	0.000832	CcSEcCtD
Pazopanib—Rash—Methylprednisolone—psoriatic arthritis	0.000281	0.000832	CcSEcCtD
Pazopanib—Dermatitis—Methylprednisolone—psoriatic arthritis	0.000281	0.000831	CcSEcCtD
Pazopanib—Headache—Triamcinolone—psoriatic arthritis	0.00028	0.000828	CcSEcCtD
Pazopanib—FGFR1—DAP12 interactions—HLA-B—psoriatic arthritis	0.00028	0.0029	CbGpPWpGaD
Pazopanib—Headache—Methylprednisolone—psoriatic arthritis	0.00028	0.000826	CcSEcCtD
Pazopanib—Abdominal pain—Prednisone—psoriatic arthritis	0.000279	0.000826	CcSEcCtD
Pazopanib—PDGFRA—DAP12 interactions—HLA-B—psoriatic arthritis	0.000279	0.00289	CbGpPWpGaD
Pazopanib—Diarrhoea—Dexamethasone—psoriatic arthritis	0.000278	0.000821	CcSEcCtD
Pazopanib—Diarrhoea—Betamethasone—psoriatic arthritis	0.000278	0.000821	CcSEcCtD
Pazopanib—FGFR3—Adaptive Immune System—HLA-C—psoriatic arthritis	0.000275	0.00286	CbGpPWpGaD
Pazopanib—FGF1—Immune System—MEFV—psoriatic arthritis	0.000271	0.00281	CbGpPWpGaD
Pazopanib—UGT1A1—Aryl Hydrocarbon Receptor Pathway—TNF—psoriatic arthritis	0.000271	0.00281	CbGpPWpGaD
Pazopanib—Musculoskeletal discomfort—Methotrexate—psoriatic arthritis	0.000269	0.000796	CcSEcCtD
Pazopanib—Dizziness—Betamethasone—psoriatic arthritis	0.000268	0.000793	CcSEcCtD
Pazopanib—Dizziness—Dexamethasone—psoriatic arthritis	0.000268	0.000793	CcSEcCtD
Pazopanib—ITK—Innate Immune System—CRP—psoriatic arthritis	0.000267	0.00277	CbGpPWpGaD
Pazopanib—Insomnia—Methotrexate—psoriatic arthritis	0.000267	0.00079	CcSEcCtD
Pazopanib—Nausea—Triamcinolone—psoriatic arthritis	0.000266	0.000785	CcSEcCtD
Pazopanib—Paraesthesia—Methotrexate—psoriatic arthritis	0.000265	0.000784	CcSEcCtD
Pazopanib—Nausea—Methylprednisolone—psoriatic arthritis	0.000265	0.000784	CcSEcCtD
Pazopanib—Dyspnoea—Methotrexate—psoriatic arthritis	0.000263	0.000778	CcSEcCtD
Pazopanib—Somnolence—Methotrexate—psoriatic arthritis	0.000263	0.000776	CcSEcCtD
Pazopanib—Dyspepsia—Methotrexate—psoriatic arthritis	0.00026	0.000769	CcSEcCtD
Pazopanib—LCK—Innate Immune System—MEFV—psoriatic arthritis	0.000259	0.00269	CbGpPWpGaD
Pazopanib—Vomiting—Dexamethasone—psoriatic arthritis	0.000258	0.000763	CcSEcCtD
Pazopanib—Vomiting—Betamethasone—psoriatic arthritis	0.000258	0.000763	CcSEcCtD
Pazopanib—Decreased appetite—Methotrexate—psoriatic arthritis	0.000257	0.000759	CcSEcCtD
Pazopanib—Rash—Dexamethasone—psoriatic arthritis	0.000256	0.000756	CcSEcCtD
Pazopanib—Rash—Betamethasone—psoriatic arthritis	0.000256	0.000756	CcSEcCtD
Pazopanib—Dermatitis—Dexamethasone—psoriatic arthritis	0.000256	0.000756	CcSEcCtD
Pazopanib—Dermatitis—Betamethasone—psoriatic arthritis	0.000256	0.000756	CcSEcCtD
Pazopanib—Gastrointestinal disorder—Methotrexate—psoriatic arthritis	0.000255	0.000754	CcSEcCtD
Pazopanib—Fatigue—Methotrexate—psoriatic arthritis	0.000255	0.000753	CcSEcCtD
Pazopanib—Headache—Dexamethasone—psoriatic arthritis	0.000254	0.000752	CcSEcCtD
Pazopanib—Headache—Betamethasone—psoriatic arthritis	0.000254	0.000752	CcSEcCtD
Pazopanib—Asthenia—Prednisone—psoriatic arthritis	0.000254	0.00075	CcSEcCtD
Pazopanib—Pain—Methotrexate—psoriatic arthritis	0.000253	0.000747	CcSEcCtD
Pazopanib—PDGFRB—DAP12 interactions—HLA-B—psoriatic arthritis	0.000251	0.00261	CbGpPWpGaD
Pazopanib—Pruritus—Prednisone—psoriatic arthritis	0.00025	0.000739	CcSEcCtD
Pazopanib—FGF1—Adaptive Immune System—REL—psoriatic arthritis	0.000249	0.00258	CbGpPWpGaD
Pazopanib—MAP3K2—MAPK Signaling Pathway—TNF—psoriatic arthritis	0.000246	0.00255	CbGpPWpGaD
Pazopanib—ITK—Adaptive Immune System—HLA-DRB1—psoriatic arthritis	0.000246	0.00255	CbGpPWpGaD
Pazopanib—Diarrhoea—Prednisone—psoriatic arthritis	0.000242	0.000715	CcSEcCtD
Pazopanib—Gastrointestinal pain—Methotrexate—psoriatic arthritis	0.000242	0.000714	CcSEcCtD
Pazopanib—Nausea—Dexamethasone—psoriatic arthritis	0.000241	0.000713	CcSEcCtD
Pazopanib—Nausea—Betamethasone—psoriatic arthritis	0.000241	0.000713	CcSEcCtD
Pazopanib—FGF1—Innate Immune System—HLA-C—psoriatic arthritis	0.000238	0.00247	CbGpPWpGaD
Pazopanib—LCK—Cytokine Signaling in Immune system—HLA-C—psoriatic arthritis	0.000236	0.00245	CbGpPWpGaD
Pazopanib—Dizziness—Prednisone—psoriatic arthritis	0.000234	0.000691	CcSEcCtD
Pazopanib—Abdominal pain—Methotrexate—psoriatic arthritis	0.000234	0.00069	CcSEcCtD
Pazopanib—FGF1—Adaptive Immune System—HLA-C—psoriatic arthritis	0.000229	0.00237	CbGpPWpGaD
Pazopanib—Vomiting—Prednisone—psoriatic arthritis	0.000225	0.000664	CcSEcCtD
Pazopanib—FGFR2—Immune System—MEFV—psoriatic arthritis	0.000224	0.00233	CbGpPWpGaD
Pazopanib—Rash—Prednisone—psoriatic arthritis	0.000223	0.000659	CcSEcCtD
Pazopanib—Dermatitis—Prednisone—psoriatic arthritis	0.000223	0.000658	CcSEcCtD
Pazopanib—Headache—Prednisone—psoriatic arthritis	0.000221	0.000655	CcSEcCtD
Pazopanib—KIT—Immune System—MEFV—psoriatic arthritis	0.00022	0.00229	CbGpPWpGaD
Pazopanib—ITK—Immune System—NOD2—psoriatic arthritis	0.000219	0.00227	CbGpPWpGaD
Pazopanib—FGFR2—MicroRNAs in cardiomyocyte hypertrophy—TNF—psoriatic arthritis	0.000218	0.00226	CbGpPWpGaD
Pazopanib—PDGFRA—Allograft Rejection—TNF—psoriatic arthritis	0.000213	0.00221	CbGpPWpGaD
Pazopanib—LYN—Cytokine Signaling in Immune system—NOD2—psoriatic arthritis	0.000212	0.0022	CbGpPWpGaD
Pazopanib—Asthenia—Methotrexate—psoriatic arthritis	0.000212	0.000626	CcSEcCtD
Pazopanib—FGFR3—Innate Immune System—NOD2—psoriatic arthritis	0.000211	0.00219	CbGpPWpGaD
Pazopanib—Nausea—Prednisone—psoriatic arthritis	0.00021	0.000621	CcSEcCtD
Pazopanib—FGFR1—Immune System—MEFV—psoriatic arthritis	0.000209	0.00217	CbGpPWpGaD
Pazopanib—Pruritus—Methotrexate—psoriatic arthritis	0.000209	0.000618	CcSEcCtD
Pazopanib—PDGFRA—Immune System—MEFV—psoriatic arthritis	0.000209	0.00216	CbGpPWpGaD
Pazopanib—FGFR2—Adaptive Immune System—REL—psoriatic arthritis	0.000206	0.00213	CbGpPWpGaD
Pazopanib—KIT—Adaptive Immune System—REL—psoriatic arthritis	0.000202	0.0021	CbGpPWpGaD
Pazopanib—Diarrhoea—Methotrexate—psoriatic arthritis	0.000202	0.000597	CcSEcCtD
Pazopanib—LCK—DAP12 interactions—HLA-B—psoriatic arthritis	0.000202	0.00209	CbGpPWpGaD
Pazopanib—ABCB1—Allograft Rejection—HLA-B—psoriatic arthritis	0.000202	0.00209	CbGpPWpGaD
Pazopanib—FGFR2—Innate Immune System—HLA-C—psoriatic arthritis	0.000197	0.00205	CbGpPWpGaD
Pazopanib—Dizziness—Methotrexate—psoriatic arthritis	0.000195	0.000577	CcSEcCtD
Pazopanib—KIT—Innate Immune System—HLA-C—psoriatic arthritis	0.000194	0.00201	CbGpPWpGaD
Pazopanib—FGFR1—Adaptive Immune System—REL—psoriatic arthritis	0.000192	0.00199	CbGpPWpGaD
Pazopanib—PDGFRA—Adaptive Immune System—REL—psoriatic arthritis	0.000191	0.00198	CbGpPWpGaD
Pazopanib—FGFR2—Adaptive Immune System—HLA-C—psoriatic arthritis	0.000189	0.00196	CbGpPWpGaD
Pazopanib—PDGFRB—Immune System—MEFV—psoriatic arthritis	0.000188	0.00195	CbGpPWpGaD
Pazopanib—Vomiting—Methotrexate—psoriatic arthritis	0.000188	0.000555	CcSEcCtD
Pazopanib—ABCB1—HIF-1-alpha transcription factor network—NOS2—psoriatic arthritis	0.000188	0.00195	CbGpPWpGaD
Pazopanib—Rash—Methotrexate—psoriatic arthritis	0.000186	0.000551	CcSEcCtD
Pazopanib—Dermatitis—Methotrexate—psoriatic arthritis	0.000186	0.00055	CcSEcCtD
Pazopanib—KIT—Adaptive Immune System—HLA-C—psoriatic arthritis	0.000186	0.00193	CbGpPWpGaD
Pazopanib—Headache—Methotrexate—psoriatic arthritis	0.000185	0.000547	CcSEcCtD
Pazopanib—LYN—Immune System—MEFV—psoriatic arthritis	0.000184	0.00191	CbGpPWpGaD
Pazopanib—FGFR1—Innate Immune System—HLA-C—psoriatic arthritis	0.000184	0.00191	CbGpPWpGaD
Pazopanib—PDGFRA—Innate Immune System—HLA-C—psoriatic arthritis	0.000183	0.0019	CbGpPWpGaD
Pazopanib—FGFR3—Immune System—REL—psoriatic arthritis	0.000182	0.00188	CbGpPWpGaD
Pazopanib—FGFR1—Adaptive Immune System—HLA-C—psoriatic arthritis	0.000177	0.00183	CbGpPWpGaD
Pazopanib—ITK—Immune System—HLA-B—psoriatic arthritis	0.000176	0.00183	CbGpPWpGaD
Pazopanib—PDGFRA—Adaptive Immune System—HLA-C—psoriatic arthritis	0.000176	0.00183	CbGpPWpGaD
Pazopanib—Nausea—Methotrexate—psoriatic arthritis	0.000175	0.000519	CcSEcCtD
Pazopanib—FGF1—Innate Immune System—NOD2—psoriatic arthritis	0.000175	0.00182	CbGpPWpGaD
Pazopanib—LCK—Cytokine Signaling in Immune system—NOD2—psoriatic arthritis	0.000174	0.0018	CbGpPWpGaD
Pazopanib—PDGFRB—Adaptive Immune System—REL—psoriatic arthritis	0.000172	0.00179	CbGpPWpGaD
Pazopanib—ABCB1—Allograft Rejection—HLA-DRB1—psoriatic arthritis	0.000171	0.00177	CbGpPWpGaD
Pazopanib—LYN—Cytokine Signaling in Immune system—HLA-B—psoriatic arthritis	0.000171	0.00177	CbGpPWpGaD
Pazopanib—FGFR3—Innate Immune System—HLA-B—psoriatic arthritis	0.00017	0.00176	CbGpPWpGaD
Pazopanib—LYN—Adaptive Immune System—REL—psoriatic arthritis	0.000169	0.00175	CbGpPWpGaD
Pazopanib—FGFR3—Immune System—HLA-C—psoriatic arthritis	0.000167	0.00173	CbGpPWpGaD
Pazopanib—PDGFRB—Innate Immune System—HLA-C—psoriatic arthritis	0.000165	0.00171	CbGpPWpGaD
Pazopanib—FGFR3—Adaptive Immune System—HLA-B—psoriatic arthritis	0.000163	0.00169	CbGpPWpGaD
Pazopanib—MAP2K5—MAPK Signaling Pathway—TNF—psoriatic arthritis	0.000163	0.00169	CbGpPWpGaD
Pazopanib—LYN—Innate Immune System—HLA-C—psoriatic arthritis	0.000162	0.00168	CbGpPWpGaD
Pazopanib—PDGFRB—Adaptive Immune System—HLA-C—psoriatic arthritis	0.000159	0.00165	CbGpPWpGaD
Pazopanib—ITK—Immune System—CRP—psoriatic arthritis	0.000156	0.00162	CbGpPWpGaD
Pazopanib—LYN—Adaptive Immune System—HLA-C—psoriatic arthritis	0.000155	0.00161	CbGpPWpGaD
Pazopanib—LCK—Immune System—MEFV—psoriatic arthritis	0.000151	0.00156	CbGpPWpGaD
Pazopanib—FGF1—Immune System—REL—psoriatic arthritis	0.000151	0.00156	CbGpPWpGaD
Pazopanib—FGFR3—Innate Immune System—CRP—psoriatic arthritis	0.00015	0.00155	CbGpPWpGaD
Pazopanib—ITK—Immune System—HLA-DRB1—psoriatic arthritis	0.000149	0.00155	CbGpPWpGaD
Pazopanib—FGFR2—Innate Immune System—NOD2—psoriatic arthritis	0.000145	0.0015	CbGpPWpGaD
Pazopanib—LYN—Cytokine Signaling in Immune system—HLA-DRB1—psoriatic arthritis	0.000144	0.0015	CbGpPWpGaD
Pazopanib—KIT—Innate Immune System—NOD2—psoriatic arthritis	0.000142	0.00148	CbGpPWpGaD
Pazopanib—FGF1—Innate Immune System—HLA-B—psoriatic arthritis	0.000141	0.00146	CbGpPWpGaD
Pazopanib—LCK—Cytokine Signaling in Immune system—HLA-B—psoriatic arthritis	0.00014	0.00145	CbGpPWpGaD
Pazopanib—FGF1—Immune System—HLA-C—psoriatic arthritis	0.000139	0.00144	CbGpPWpGaD
Pazopanib—LCK—Adaptive Immune System—REL—psoriatic arthritis	0.000138	0.00143	CbGpPWpGaD
Pazopanib—FGFR3—Adaptive Immune System—HLA-DRB1—psoriatic arthritis	0.000138	0.00143	CbGpPWpGaD
Pazopanib—FGF1—Integrated Pancreatic Cancer Pathway—TNF—psoriatic arthritis	0.000137	0.00142	CbGpPWpGaD
Pazopanib—FGF1—Adaptive Immune System—HLA-B—psoriatic arthritis	0.000135	0.0014	CbGpPWpGaD
Pazopanib—FGFR1—Innate Immune System—NOD2—psoriatic arthritis	0.000135	0.0014	CbGpPWpGaD
Pazopanib—PDGFRA—Innate Immune System—NOD2—psoriatic arthritis	0.000135	0.0014	CbGpPWpGaD
Pazopanib—LCK—Innate Immune System—HLA-C—psoriatic arthritis	0.000133	0.00138	CbGpPWpGaD
Pazopanib—LCK—Adaptive Immune System—HLA-C—psoriatic arthritis	0.000127	0.00132	CbGpPWpGaD
Pazopanib—FGFR2—Immune System—REL—psoriatic arthritis	0.000125	0.00129	CbGpPWpGaD
Pazopanib—FGF1—Innate Immune System—CRP—psoriatic arthritis	0.000125	0.00129	CbGpPWpGaD
Pazopanib—FGFR3—Immune System—NOD2—psoriatic arthritis	0.000123	0.00127	CbGpPWpGaD
Pazopanib—KIT—Immune System—REL—psoriatic arthritis	0.000123	0.00127	CbGpPWpGaD
Pazopanib—PDGFRB—Innate Immune System—NOD2—psoriatic arthritis	0.000121	0.00126	CbGpPWpGaD
Pazopanib—LYN—Innate Immune System—NOD2—psoriatic arthritis	0.000119	0.00123	CbGpPWpGaD
Pazopanib—LCK—Cytokine Signaling in Immune system—HLA-DRB1—psoriatic arthritis	0.000118	0.00123	CbGpPWpGaD
Pazopanib—FGFR1—MAPK Signaling Pathway—TNF—psoriatic arthritis	0.000117	0.00121	CbGpPWpGaD
Pazopanib—FGFR2—Innate Immune System—HLA-B—psoriatic arthritis	0.000117	0.00121	CbGpPWpGaD
Pazopanib—LIMK2—Developmental Biology—TNF—psoriatic arthritis	0.000117	0.00121	CbGpPWpGaD
Pazopanib—FGFR1—Immune System—REL—psoriatic arthritis	0.000116	0.00121	CbGpPWpGaD
Pazopanib—PDGFRA—Immune System—REL—psoriatic arthritis	0.000116	0.0012	CbGpPWpGaD
Pazopanib—FGFR2—Immune System—HLA-C—psoriatic arthritis	0.000115	0.00119	CbGpPWpGaD
Pazopanib—FGF1—Adaptive Immune System—HLA-DRB1—psoriatic arthritis	0.000115	0.00119	CbGpPWpGaD
Pazopanib—KIT—Innate Immune System—HLA-B—psoriatic arthritis	0.000115	0.00119	CbGpPWpGaD
Pazopanib—KIT—Immune System—HLA-C—psoriatic arthritis	0.000113	0.00117	CbGpPWpGaD
Pazopanib—FGFR2—Adaptive Immune System—HLA-B—psoriatic arthritis	0.000112	0.00116	CbGpPWpGaD
Pazopanib—KIT—Adaptive Immune System—HLA-B—psoriatic arthritis	0.00011	0.00114	CbGpPWpGaD
Pazopanib—EPHB6—Developmental Biology—TNF—psoriatic arthritis	0.00011	0.00114	CbGpPWpGaD
Pazopanib—FGFR1—Innate Immune System—HLA-B—psoriatic arthritis	0.000109	0.00113	CbGpPWpGaD
Pazopanib—PDGFRA—Innate Immune System—HLA-B—psoriatic arthritis	0.000108	0.00112	CbGpPWpGaD
Pazopanib—FGFR1—Immune System—HLA-C—psoriatic arthritis	0.000107	0.00111	CbGpPWpGaD
Pazopanib—PDGFRA—Immune System—HLA-C—psoriatic arthritis	0.000107	0.00111	CbGpPWpGaD
Pazopanib—FGFR1—Integrated Pancreatic Cancer Pathway—TNF—psoriatic arthritis	0.000105	0.00109	CbGpPWpGaD
Pazopanib—PDGFRA—Integrated Pancreatic Cancer Pathway—TNF—psoriatic arthritis	0.000105	0.00109	CbGpPWpGaD
Pazopanib—PDGFRB—MAPK Signaling Pathway—TNF—psoriatic arthritis	0.000105	0.00109	CbGpPWpGaD
Pazopanib—PDGFRB—Immune System—REL—psoriatic arthritis	0.000105	0.00108	CbGpPWpGaD
Pazopanib—FGFR1—Adaptive Immune System—HLA-B—psoriatic arthritis	0.000104	0.00108	CbGpPWpGaD
Pazopanib—PDGFRA—Adaptive Immune System—HLA-B—psoriatic arthritis	0.000104	0.00108	CbGpPWpGaD
Pazopanib—FGFR2—Innate Immune System—CRP—psoriatic arthritis	0.000103	0.00107	CbGpPWpGaD
Pazopanib—LYN—Immune System—REL—psoriatic arthritis	0.000102	0.00106	CbGpPWpGaD
Pazopanib—FGF1—Immune System—NOD2—psoriatic arthritis	0.000102	0.00106	CbGpPWpGaD
Pazopanib—KIT—Innate Immune System—CRP—psoriatic arthritis	0.000101	0.00105	CbGpPWpGaD
Pazopanib—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—psoriatic arthritis	9.92e-05	0.00103	CbGpPWpGaD
Pazopanib—CYP1A2—Aryl Hydrocarbon Receptor—TNF—psoriatic arthritis	9.92e-05	0.00103	CbGpPWpGaD
Pazopanib—FGFR3—Immune System—HLA-B—psoriatic arthritis	9.88e-05	0.00102	CbGpPWpGaD
Pazopanib—PDGFRB—Innate Immune System—HLA-B—psoriatic arthritis	9.77e-05	0.00101	CbGpPWpGaD
Pazopanib—LCK—Innate Immune System—NOD2—psoriatic arthritis	9.75e-05	0.00101	CbGpPWpGaD
Pazopanib—PDGFRB—Immune System—HLA-C—psoriatic arthritis	9.62e-05	0.000998	CbGpPWpGaD
Pazopanib—FGFR1—Innate Immune System—CRP—psoriatic arthritis	9.61e-05	0.000997	CbGpPWpGaD
Pazopanib—PDGFRA—Innate Immune System—CRP—psoriatic arthritis	9.59e-05	0.000994	CbGpPWpGaD
Pazopanib—LYN—Innate Immune System—HLA-B—psoriatic arthritis	9.57e-05	0.000992	CbGpPWpGaD
Pazopanib—FGFR2—Adaptive Immune System—HLA-DRB1—psoriatic arthritis	9.48e-05	0.000983	CbGpPWpGaD
Pazopanib—LYN—Immune System—HLA-C—psoriatic arthritis	9.42e-05	0.000977	CbGpPWpGaD
Pazopanib—PDGFRB—Adaptive Immune System—HLA-B—psoriatic arthritis	9.38e-05	0.000973	CbGpPWpGaD
Pazopanib—KIT—Adaptive Immune System—HLA-DRB1—psoriatic arthritis	9.31e-05	0.000966	CbGpPWpGaD
Pazopanib—LYN—Adaptive Immune System—HLA-B—psoriatic arthritis	9.19e-05	0.000953	CbGpPWpGaD
Pazopanib—FGFR1—Adaptive Immune System—HLA-DRB1—psoriatic arthritis	8.84e-05	0.000917	CbGpPWpGaD
Pazopanib—PDGFRA—Adaptive Immune System—HLA-DRB1—psoriatic arthritis	8.82e-05	0.000914	CbGpPWpGaD
Pazopanib—FGFR3—Immune System—CRP—psoriatic arthritis	8.73e-05	0.000906	CbGpPWpGaD
Pazopanib—PDGFRB—Innate Immune System—CRP—psoriatic arthritis	8.64e-05	0.000896	CbGpPWpGaD
Pazopanib—LYN—Hemostasis—NOS2—psoriatic arthritis	8.56e-05	0.000888	CbGpPWpGaD
Pazopanib—LYN—Innate Immune System—CRP—psoriatic arthritis	8.45e-05	0.000877	CbGpPWpGaD
Pazopanib—FGFR2—Immune System—NOD2—psoriatic arthritis	8.45e-05	0.000876	CbGpPWpGaD
Pazopanib—LCK—Immune System—REL—psoriatic arthritis	8.39e-05	0.00087	CbGpPWpGaD
Pazopanib—FGFR3—Immune System—HLA-DRB1—psoriatic arthritis	8.36e-05	0.000867	CbGpPWpGaD
Pazopanib—KIT—Immune System—NOD2—psoriatic arthritis	8.3e-05	0.000861	CbGpPWpGaD
Pazopanib—FGF1—Immune System—HLA-B—psoriatic arthritis	8.21e-05	0.000851	CbGpPWpGaD
Pazopanib—ABCB1—Allograft Rejection—TNF—psoriatic arthritis	8.06e-05	0.000836	CbGpPWpGaD
Pazopanib—PDGFRB—Adaptive Immune System—HLA-DRB1—psoriatic arthritis	7.94e-05	0.000824	CbGpPWpGaD
Pazopanib—FGFR1—Immune System—NOD2—psoriatic arthritis	7.88e-05	0.000817	CbGpPWpGaD
Pazopanib—PDGFRA—Immune System—NOD2—psoriatic arthritis	7.85e-05	0.000815	CbGpPWpGaD
Pazopanib—LCK—Innate Immune System—HLA-B—psoriatic arthritis	7.84e-05	0.000813	CbGpPWpGaD
Pazopanib—LYN—Adaptive Immune System—HLA-DRB1—psoriatic arthritis	7.78e-05	0.000806	CbGpPWpGaD
Pazopanib—LCK—Immune System—HLA-C—psoriatic arthritis	7.72e-05	0.000801	CbGpPWpGaD
Pazopanib—LCK—Adaptive Immune System—HLA-B—psoriatic arthritis	7.53e-05	0.000781	CbGpPWpGaD
Pazopanib—FGFR3—Disease—NOS2—psoriatic arthritis	7.35e-05	0.000762	CbGpPWpGaD
Pazopanib—FGF1—Immune System—CRP—psoriatic arthritis	7.26e-05	0.000753	CbGpPWpGaD
Pazopanib—PDGFRB—Immune System—NOD2—psoriatic arthritis	7.08e-05	0.000734	CbGpPWpGaD
Pazopanib—LCK—Hemostasis—NOS2—psoriatic arthritis	7.02e-05	0.000728	CbGpPWpGaD
Pazopanib—FGF1—Immune System—HLA-DRB1—psoriatic arthritis	6.95e-05	0.000721	CbGpPWpGaD
Pazopanib—LCK—Innate Immune System—CRP—psoriatic arthritis	6.93e-05	0.000719	CbGpPWpGaD
Pazopanib—LYN—Immune System—NOD2—psoriatic arthritis	6.93e-05	0.000719	CbGpPWpGaD
Pazopanib—FGFR2—Immune System—HLA-B—psoriatic arthritis	6.79e-05	0.000705	CbGpPWpGaD
Pazopanib—KDR—Developmental Biology—TNF—psoriatic arthritis	6.69e-05	0.000694	CbGpPWpGaD
Pazopanib—KIT—Immune System—HLA-B—psoriatic arthritis	6.67e-05	0.000692	CbGpPWpGaD
Pazopanib—LCK—Adaptive Immune System—HLA-DRB1—psoriatic arthritis	6.37e-05	0.000661	CbGpPWpGaD
Pazopanib—FGFR1—Immune System—HLA-B—psoriatic arthritis	6.33e-05	0.000657	CbGpPWpGaD
Pazopanib—PDGFRA—Immune System—HLA-B—psoriatic arthritis	6.32e-05	0.000655	CbGpPWpGaD
Pazopanib—FGF1—Disease—NOS2—psoriatic arthritis	6.11e-05	0.000634	CbGpPWpGaD
Pazopanib—FGFR2—Immune System—CRP—psoriatic arthritis	6.01e-05	0.000623	CbGpPWpGaD
Pazopanib—KIT—Immune System—CRP—psoriatic arthritis	5.9e-05	0.000612	CbGpPWpGaD
Pazopanib—FGFR2—Immune System—HLA-DRB1—psoriatic arthritis	5.75e-05	0.000596	CbGpPWpGaD
Pazopanib—PDGFRB—Immune System—HLA-B—psoriatic arthritis	5.69e-05	0.00059	CbGpPWpGaD
Pazopanib—LCK—Immune System—NOD2—psoriatic arthritis	5.68e-05	0.000589	CbGpPWpGaD
Pazopanib—KIT—Immune System—HLA-DRB1—psoriatic arthritis	5.65e-05	0.000586	CbGpPWpGaD
Pazopanib—FGFR1—Immune System—CRP—psoriatic arthritis	5.6e-05	0.000581	CbGpPWpGaD
Pazopanib—PDGFRA—Immune System—CRP—psoriatic arthritis	5.58e-05	0.000579	CbGpPWpGaD
Pazopanib—LYN—Immune System—HLA-B—psoriatic arthritis	5.57e-05	0.000578	CbGpPWpGaD
Pazopanib—FGFR1—Immune System—HLA-DRB1—psoriatic arthritis	5.36e-05	0.000556	CbGpPWpGaD
Pazopanib—PDGFRA—Immune System—HLA-DRB1—psoriatic arthritis	5.35e-05	0.000555	CbGpPWpGaD
Pazopanib—FGFR2—Disease—NOS2—psoriatic arthritis	5.06e-05	0.000524	CbGpPWpGaD
Pazopanib—PDGFRB—Immune System—CRP—psoriatic arthritis	5.03e-05	0.000522	CbGpPWpGaD
Pazopanib—KIT—Disease—NOS2—psoriatic arthritis	4.97e-05	0.000515	CbGpPWpGaD
Pazopanib—FGFR1—Developmental Biology—TNF—psoriatic arthritis	4.93e-05	0.000511	CbGpPWpGaD
Pazopanib—LYN—Immune System—CRP—psoriatic arthritis	4.92e-05	0.000511	CbGpPWpGaD
Pazopanib—PDGFRB—Immune System—HLA-DRB1—psoriatic arthritis	4.82e-05	0.0005	CbGpPWpGaD
Pazopanib—LYN—Immune System—HLA-DRB1—psoriatic arthritis	4.72e-05	0.000489	CbGpPWpGaD
Pazopanib—FGFR1—Disease—NOS2—psoriatic arthritis	4.71e-05	0.000489	CbGpPWpGaD
Pazopanib—PDGFRA—Disease—NOS2—psoriatic arthritis	4.7e-05	0.000488	CbGpPWpGaD
Pazopanib—LCK—Immune System—HLA-B—psoriatic arthritis	4.57e-05	0.000474	CbGpPWpGaD
Pazopanib—LYN—Developmental Biology—TNF—psoriatic arthritis	4.33e-05	0.000449	CbGpPWpGaD
Pazopanib—PDGFRB—Disease—NOS2—psoriatic arthritis	4.23e-05	0.000439	CbGpPWpGaD
Pazopanib—LCK—Immune System—CRP—psoriatic arthritis	4.04e-05	0.000419	CbGpPWpGaD
Pazopanib—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—psoriatic arthritis	3.98e-05	0.000413	CbGpPWpGaD
Pazopanib—LCK—Immune System—HLA-DRB1—psoriatic arthritis	3.87e-05	0.000401	CbGpPWpGaD
Pazopanib—LCK—Disease—NOS2—psoriatic arthritis	3.4e-05	0.000352	CbGpPWpGaD
